Pages that link to "Q39186123"
Jump to navigation
Jump to search
The following pages link to Andreas Lundqvist (Q39186123):
Displaying 50 items.
- Cancer classification using the Immunoscore: a worldwide task force (Q21245495) (← links)
- HLA-dependent tumour development: a role for tumour associate macrophages? (Q27022124) (← links)
- Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells (Q28550076) (← links)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (Q28553703) (← links)
- Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis (Q30315505) (← links)
- Overexpression and functional characterisation of the human melanocortin 4 receptor in Sf9 cells. (Q33206629) (← links)
- Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis (Q33244809) (← links)
- Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma (Q33591598) (← links)
- Correlation between HLA-A2 gene frequency, latitude, ovarian and prostate cancer mortality rates. (Q33844426) (← links)
- Major histocompatibility complex-I expression on embryonic stem cell-derived vascular progenitor cells is critical for syngeneic transplant survival. (Q34184100) (← links)
- Dendritic cell regulation of NK-cell responses involves lymphotoxin-α, IL-12, and TGF-β. (Q34467270) (← links)
- Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells (Q34605718) (← links)
- Gene-modified dendritic cells for immunotherapy against cancer (Q35039002) (← links)
- Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer Cells (Q35098303) (← links)
- Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors (Q35751074) (← links)
- Allogeneic hematopoietic cell transplantation as immunotherapy for solid tumors: current status and future directions (Q36185116) (← links)
- Opposing consequences of signaling through EGF family members: Escape from CTLs could be a bait for NK cells (Q36388560) (← links)
- Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells (Q36471611) (← links)
- A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. (Q36626087) (← links)
- Primitive quiescent CD34 cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib (Q37071112) (← links)
- Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells (Q37234615) (← links)
- IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells. (Q37261189) (← links)
- Natural killer cell immunotherapy for cancer: a new hope (Q37352914) (← links)
- Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF. (Q37480306) (← links)
- Regulation of TRAIL-receptor expression by the ubiquitin-proteasome system. (Q38260461) (← links)
- Tissue distribution and differential expression of melanocortin 1 receptor, a malignant melanoma marker. (Q38289468) (← links)
- Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists. (Q38672403) (← links)
- CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo (Q38945158) (← links)
- Human anaplastic thyroid carcinoma cells are sensitive to NK cell-mediated lysis via ULBP2/5/6 and chemoattract NK cells (Q38957413) (← links)
- Gap junction intercellular communications regulate NK cell activation and modulate NK cytotoxic capacity (Q39038562) (← links)
- A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells. (Q39149515) (← links)
- Melanoma-educated CD14 cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms (Q39158003) (← links)
- Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling (Q39179377) (← links)
- Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: On being in the right place at the right time, with resilience. (Q39281940) (← links)
- HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines (Q39402352) (← links)
- Cripto-1 vaccination elicits protective immunity against metastatic melanoma (Q39550346) (← links)
- Cutting edge: bortezomib-treated tumors sensitized to NK cell apoptosis paradoxically acquire resistance to antigen-specific T cells (Q39760375) (← links)
- Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity (Q40253974) (← links)
- Chromatography on cells and biomolecular assemblies. (Q41657372) (← links)
- Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma (Q41714691) (← links)
- Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours (Q41946577) (← links)
- Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients (Q42241761) (← links)
- Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation (Q42379867) (← links)
- Correction to: Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma (Q44362549) (← links)
- Allogeneic tumor-dendritic cell fusion vaccines for generation of broad prostate cancer T-cell responses (Q45010454) (← links)
- Nonviral and viral gene transfer into different subsets of human dendritic cells yield comparable efficiency of transfection (Q45173286) (← links)
- Mature dendritic cells induce tumor-specific type 1 regulatory T cells (Q45882892) (← links)
- Mature dendritic cells are protected from Fas/CD95-mediated apoptosis by upregulation of Bcl-X(L). (Q45884928) (← links)
- Development of a technology platform for large-scale clinical grade production of DC. (Q45886684) (← links)
- Recombinant adenovirus vector activates and protects human monocyte-derived dendritic cells from apoptosis (Q45889359) (← links)